标题
PD-L1 Is Preferentially Expressed in PIT-1 Positive Pituitary Neuroendocrine Tumours
作者
关键词
-
出版物
ENDOCRINE PATHOLOGY
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-03-11
DOI
10.1007/s12022-021-09673-2
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Human CD4+ T cell subsets differ in their abilities to cross endothelial and epithelial brain barriers in vitro
- (2020) Hideaki Nishihara et al. Fluids and Barriers of the CNS
- Utility of GATA-3 Expression in the Analysis of Pituitary Neuroendocrine Tumour (PitNET) Transcription Factors
- (2020) John Turchini et al. ENDOCRINE PATHOLOGY
- Cytokeratin Profiles in Pituitary Neuroendocrine Tumors
- (2020) Sylvia L. Asa et al. HUMAN PATHOLOGY
- Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study
- (2020) Nazanin Majd et al. Journal for ImmunoTherapy of Cancer
- Immune checkpoint inhibitor-induced colitis: A comprehensive review
- (2019) Aniruddh Som et al. World Journal of Clinical Cases
- Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases
- (2019) Dennis P. O’Malley et al. MODERN PATHOLOGY
- An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors
- (2019) Omalkhaire M. Alshaikh et al. ENDOCRINE PATHOLOGY
- Non-functioning pituitary adenomas: indications for pituitary surgery and post-surgical management
- (2019) Daniela Esposito et al. Pituitary
- The Treatment of Refractory Pituitary Adenomas
- (2019) Congxin Dai et al. Frontiers in Endocrinology
- Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience
- (2019) G Giuffrida et al. Endocrine Connections
- MANAGEMENT OF ENDOCRINE DISEASE: Immune check point inhibitors-induced hypophysitis
- (2019) Frédérique Albarel et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016
- (2018) Ann McCormack et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- The expression profile of PD-L1 and CD8+ lymphocyte in pituitary adenomas indicating for immunotherapy
- (2018) Peng-fei Wang et al. JOURNAL OF NEURO-ONCOLOGY
- Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens
- (2018) Romualdo Barroso-Sousa et al. JAMA Oncology
- Marked response of a hypermutated adrenocorticotropic hormone-secreting pituitary carcinoma to ipilimumab and nivolumab
- (2018) Andrew L Lin et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal
- (2017) S L Asa et al. ENDOCRINE-RELATED CANCER
- The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma
- (2017) Emma S Scott et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Diagnosis and Treatment of Pituitary Adenomas
- (2017) Mark E. Molitch JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Outcome of Nonfunctioning Pituitary Adenomas That Regrow After Primary Treatment: A Study From Two Large UK Centers
- (2017) Metaxia Tampourlou et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability
- (2017) Hans Brunnström et al. MODERN PATHOLOGY
- PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
- (2017) Sydney R. Gordon et al. NATURE
- Histopathological classification of non-functioning pituitary neuroendocrine tumors
- (2017) Emilija Manojlovic-Gacic et al. Pituitary
- Why anti-PD1/PDL1 therapy is so effective? Another piece in the puzzle
- (2017) Antonio Marchetti et al. Journal of Thoracic Disease
- Revisitation of autoimmune hypophysitis: knowledge and uncertainties on pathophysiological and clinical aspects
- (2016) Giuseppe Bellastella et al. Pituitary
- Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors
- (2016) Yu Mei et al. Oncotarget
- Long-Term Outcome and MGMT as a Predictive Marker in 24 Patients With Atypical Pituitary Adenomas and Pituitary Carcinomas Given Treatment With Temozolomide
- (2015) Daniel Bengtsson et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina
- (2015) Oscar D. Bruno et al. International Journal of Endocrinology
- Succinate Dehydrogenase Deficiency Is Rare in Pituitary Adenomas
- (2014) Anthony J. Gill et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment
- (2012) Gérald Raverot et al. CLINICAL ENDOCRINOLOGY
- Capture, crawl, cross: the T cell code to breach the blood–brain barriers
- (2012) Britta Engelhardt et al. TRENDS IN IMMUNOLOGY
- Radiation Therapy in the Management of Pituitary Adenomas
- (2011) Jay S. Loeffler et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Natural History of Nonfunctioning Pituitary Adenomas and Incidentalomas: A Systematic Review and Metaanalysis
- (2011) M. Mercè Fernández-Balsells et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pituitary Incidentaloma: An Endocrine Society Clinical Practice Guideline
- (2011) Pamela U. Freda et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Temozolomide Treatment for Aggressive Pituitary Tumors: Correlation of Clinical Outcome with O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation and Expression
- (2010) Zachary M. Bush et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pituitary incidentalomas
- (2009) Mark E. Molitch BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started